Table 2. Characteristics of the studied patients.
Tables patients groups and characteristics. P < 0.05 is considered statistically significant.
| Characteristics | Total | SNA disease | No SNA disease | P values | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | SVA+ | SVA- | Total | SVA+ | SVA- | P1 | P2 | P3 | P3c | |||
| Patients groups | No | 333 | 51 | 21 | 30 | 282 | 21 | 261 | ||||
| % | 100 | 15.3 | 41.2 | 58.8 | 84.7 | 7.4 | 92.6 | |||||
| Age (yr) | Median | 68 | 73 | 77 | 69.5 | 67 | 74 | 66 | 0.052 | 0.059 | 0.058 | 0.178 |
| IR | 60–78 | 61–80.5 | 70–82 | 57–78 | 59–76 | 70–78 | 58–76 | |||||
| Female sex | No | 88 | 11 | 5 | 6 | 77 | 6 | 71 | 0.744 | 0.892 | 0.393 | 0.251 |
| % | 26.4 | 21.6 | 23.8 | 20.0 | 27.3 | 28.6 | 27.2 | |||||
| ACS (STEMI) | No | 217 (94) | 32 (12) | 13 (3) | 19 (9) | 185 (82) | 10 (3) | 175 (79) | 0.917 | 0.071 | 0.693 | 0.438 |
| % | 65.2 (43.3) | 62.7 (37.5) | 61.9 (23.1) | 63.3 (47.4) | 65.6 (44.3) | 47.6 (30.0) | 67.0 (45.1) | |||||
| Hypertension requiring treatment | No | 237 | 42 | 20 | 22 | 195 | 15 | 180 | 0.640 | 0.814 | 0.055 | 0.732 |
| % | 71.2 | 82.4 | 95.2 | 73.3 | 69.1 | 71.4 | 69.0 | |||||
| Prior AMI | No | 89 | 22 | 10 | 12 | 67 | 3 | 64 | 0.589 | 0.425 | 0.004 | 0.025 |
| % | 26.7 | 43.1 | 47.6 | 40.0 | 23.8 | 14.3 | 24.5 | |||||
| DM | No | 75 | 11 | 3 | 8 | 64 | 2 | 62 | 0.490 | 0.178 | 0.859 | 0.627 |
| % | 22.5 | 21.6 | 14.3 | 26.7 | 22.7 | 9.5 | 23.8 | |||||
| PAD | No | 89 | 18 | 9 | 9 | 71 | 7 | 64 | 0.344 | 0.371 | 0.133 | 0.604 |
| % | 26.7 | 35.3 | 42.9 | 30.0 | 25.2 | 33.3 | 24.5 | |||||
| Smoke | 0.189 | 0.221 | 0.693 | 0.097 | ||||||||
| Current | No | 89 | 14 | 3 | 11 | 75 | 3 | 72 | ||||
| % | 26.7 | 27.5 | 14.3 | 36.7 | 26.6 | 14.3 | 27.6 | |||||
| Former | No | 84 | 15 | 8 | 7 | 69 | 8 | 61 | ||||
| % | 25.2 | 29.4 | 38.1 | 23.3 | 24.5 | 38.1 | 23.4 | |||||
| Never | No | 160 | 22 | 10 | 12 | 138 | 10 | 128 | ||||
| % | 48.1 | 43.1 | 47.6 | 40.0 | 48.9 | 47.6 | 49.0 | |||||
| Left ventricle ejection fraction <55% | No | 128 | 26 | 12 | 14 | 102 | 13 | 89 | 0.461 | 0.011 | 0.045 | 0.756 |
| % | 38.4 | 51.0 | 57.1 | 46.7 | 36.2 | 61.9 | 34.1 | |||||
| Atrial dilatation: | 0.014 | 0.017 | 0.431 | 0.319 | ||||||||
| Na | No | 145 | 18 | 7 | 11 | 127 | 7 | 120 | ||||
| % | 43.4 | 35.3 | 33.3 | 36.7 | 45.0 | 33.3 | 46.0 | |||||
| No | No | 110 | 19 | 4 | 15 | 91 | 4 | 87 | ||||
| % | 33.0 | 37.3 | 19.1 | 50.0 | 32.3 | 19.0 | 33.3 | |||||
| Yes (mild) | No | 78 (45) | 14 (11) | 10 (7) | 4 (4) | 64 (34) | 10 (2) | 54 (32) | ||||
| % | 23.4 (57.7) | 27.4 (78.6) | 47.6 (70) | 13.3 (100) | 22.7 (53.1) | 47.7 (20) | 20.7 (59.3) | |||||
| Cholesterol level: total (mg/dl) | Median | 172 | 166 | 172 | 153 | 172 | 149 | 173 | 0.393 | 0.05 | 0.302 | 0.103 |
| IR | 143.5–200.5 | 143–190 | 155–191 | 136–186 | 144–204.5 | 136–180 | 145–208 | |||||
| Cholesterol level: HDL (mg/dl) | Median | 43 | 42 | 42 | 39.5 | 43 | 43.5 | 43 | 0.153 | 0.986 | 0.337 | 0.123 |
| IR | 35.5–52 | 35.5–49.5 | 38–50 | 32–48 | 36–52 | 37–53 | 35–52 | |||||
| TGL (mg/dl) | Median | 115 | 105 | 110 | 104 | 117 | 95 | 119 | 0.916 | 0.038 | 0.379 | 0.073 |
| IR | 82–153.5 | 83–149 | 95–145 | 79–153 | 82–155 | 63–131 | 88–159 | |||||
| Hyperthyroidism | No | 6 | 2 | 0 | 2 | 4 | 1 | 3 | 0.506 | 0.267 | 0.230 | 0.431 |
| % | 1.8 | 3.9 | 0.0 | 6.7 | 1.4 | 4.8 | 1.1 | |||||
| Renal function, creatinine clearance (ml/min) | 0.092 | 0.004 | 0.108 | 0.711 | ||||||||
| CKD stage 0–1, ≥90 | No | 78 | 9 | 1 | 8 | 69 | 2 | 67 | ||||
| % | 23.4 | 17.6 | 4.8 | 26.7 | 24.5 | 9.5 | 25.7 | |||||
| CKD stage 2, ≥60 to 89 | No | 163 | 24 | 9 | 15 | 139 | 12 | 127 | ||||
| % | 48.9 | 47.1 | 42.8 | 50.0 | 49.3 | 57.1 | 48.6 | |||||
| CKD stage 3, ≥30 to 59 | No | 79 | 13 | 8 | 5 | 66 | 6 | 60 | ||||
| % | 23.7 | 25.5 | 38.1 | 16.7 | 23.4 | 28.6 | 23.0 | |||||
| CKD stage 4, ≥15 to 29 | No | 12 | 5 | 3 | 2 | 7 | 0 | 7 | ||||
| % | 3.6 | 9.8 | 14.3 | 6.6 | 2.5 | 0.0 | 2.7 | |||||
| CKD stage 5, <15 | No | 1 | 0 | 0 | 0 | 1 | 1 | 0 | ||||
| % | 0.3 | 0.0 | 0.0 | 0.0 | 0.3 | 4.8 | 0.0 | |||||
| ACE inhibitor/ARB | No | 163 | 30 | 10 | 20 | 133 | 13 | 120 | 0.174 | 0.160 | 0.125 | 0.347 |
| % | 48.9 | 58.8 | 47.6 | 66.7 | 47.2 | 61.9 | 46.0 | |||||
| Amiodarone | No | 7 | 3 | 3 | 0 | 4 | 2 | 2 | 0.064 | 0.029 | 0.076 | 0.534 |
| % | 2.1 | 5.9 | 14.3 | 0.0 | 1.4 | 9.5 | 0.8 | |||||
| Beta-blocker | No | 112 | 24 | 11 | 13 | 88 | 9 | 79 | 0.524 | 0.231 | 0.027 | 0.524 |
| % | 33.6 | 47.1 | 52.4 | 43.3 | 31.2 | 42.9 | 30.3 | |||||
| Digoxin | No | 3 | 1 | 1 | 0 | 2 | 2 | 0 | 0.412 | 0.005 | 0.394 | 0.667 |
| % | 0.9 | 2.0 | 4.8 | 0.0 | 0.7 | 9.5 | 0.0 | |||||
| Calcium blocker | No | 59 | 10 | 3 | 7 | 49 | 7 | 42 | 0.495 | 0.067 | 0.701 | 0.986 |
| % | 17.7 | 19.6 | 14.3 | 23.3 | 17.4 | 33.3 | 16.1 | |||||
| ASA | No | 156 | 26 | 10 | 16 | 130 | 9 | 121 | 0.688 | 0.757 | 0.520 | 0.889 |
| % | 46.8 | 51.0 | 47.6 | 53.3 | 46.1 | 42.9 | 46.4 | |||||
| Thienopyridine | No | 47 | 12 | 4 | 8 | 35 | 1 | 34 | 0,739 | 0,489 | 0,036 | 0.264 |
| % | 14.1 | 23.5 | 19.0 | 26.7 | 12.4 | 4.8 | 13.0 | |||||
| IC antiarrhythmic drugs | No | 7 | 3 | 3 | 0 | 4 | 4 | 0 | 0.064 | <0.001 | 0.076 | 0.665 |
| % | 2.1 | 5.9 | 14.3 | 0.0 | 1.4 | 19.0 | 0.0 | |||||
| Statin | No | 110 | 19 | 8 | 11 | 91 | 7 | 84 | 0.917 | 0.914 | 0.486 | 0.847 |
| % | 33.0 | 37.3 | 38.1 | 36.7 | 32.3 | 33.3 | 32.2 | |||||
| Sotalol | No | 2 | 1 | 1 | 0 | 1 | 0 | 1 | 0.421 | 1 | 0.283 | 0.345 |
| % | 0.6 | 2.0 | 4.8 | 0.0 | 0,4 | 0.0 | 0.4 | |||||
Notes.
- SVA +
- subjects with a positive history of SVA
- SVA −
- subjects without a positive history of SVA
- P1
- comparison between subjects affected by SNA disease with and without SVA
- P2
- comparison between subjects not affected by SNA disease with and without SVA
- P3
- comparison between subjects with and without SNA disease
- P3c
- correction for multiple testing
- Na
- not assessable